Children with congenital adrenal hyperplasia (CAH) show abnormal patterns in bone-regulating proteins that may weaken their bones during puberty. According to Gram Research analysis, a 2026 study of 31 CAH patients found they failed to show the normal decrease in sclerostin (a bone-blocking protein) during puberty that healthy children experience, and had significantly higher osteoprotegerin levels. These changes, linked to elevated disease hormones, may impair bone mass development during critical growth years.
Children with congenital adrenal hyperplasia (CAH) who take glucocorticoid medications for long-term treatment show unusual changes in bone-regulating proteins called sclerostin and osteoprotegerin. According to Gram Research analysis, a new study found that these children don’t experience the normal drop in sclerostin levels during puberty that healthy kids do, which could affect how much bone mass they build during their teenage years. This discovery helps explain why some CAH patients struggle with bone health and may guide better treatment strategies in the future.
Key Statistics
A 2026 cross-sectional study of 31 children with congenital adrenal hyperplasia found that children with CAH had significantly higher osteoprotegerin levels compared to healthy controls (p < 0.001), suggesting altered bone metabolism.
According to research published in the European Journal of Pediatrics in 2026, children with CAH did not demonstrate the expected decline in sclerostin levels during puberty that healthy children show, potentially affecting peak bone mass acquisition.
A study of 31 CAH patients revealed that serum 17-hydroxy progesterone (a disease marker) had a significant negative effect on osteoprotegerin and positive effect on sclerostin, suggesting disease control status influences bone protein regulation.
Bone mineral density Z-scores below -1 were found in 80% of both CAH patients and control children in a 2026 study, indicating widespread bone density concerns in this population.
The Quick Take
- What they studied: How two bone-regulating proteins (sclerostin and osteoprotegerin) work differently in children with CAH compared to healthy children, and whether long-term steroid medication affects bone health.
- Who participated: 31 children with CAH (average age 11.6 years) who had been taking glucocorticoid medications for at least 5 years, compared with a similar group of healthy children of the same age and gender.
- Key finding: Children with CAH didn’t show the normal decrease in sclerostin levels during puberty that healthy kids experience, and they had higher osteoprotegerin levels. This abnormal pattern may prevent them from building strong bones during their teenage years.
- What it means for you: If you have a child with CAH, this research suggests their bones may need extra monitoring during puberty. Talk to your doctor about bone health screening and whether vitamin D or calcium supplements might help. This is early research, so treatment recommendations may evolve.
The Research Details
Researchers compared 31 children with CAH to healthy children of similar ages and genders in a single snapshot study (called a cross-sectional study). They measured two special proteins in the blood that control how bones are built and broken down: sclerostin (which slows bone formation) and osteoprotegerin (which protects bones). They also measured bone density using a special X-ray machine and looked at how steroid medication doses affected these proteins.
The study examined whether puberty status, steroid doses, vitamin D levels, and other factors influenced these bone-regulating proteins. Researchers used statistical analysis to identify which factors mattered most. This approach allowed them to take a detailed snapshot of bone metabolism in CAH patients at one point in time.
Understanding how bone-regulating proteins work in CAH patients is crucial because these children take glucocorticoid steroids long-term, which can weaken bones. By identifying specific protein changes, doctors can better understand why some CAH patients develop weak bones and potentially develop better monitoring and treatment strategies. This is the first study to examine sclerostin in CAH patients, filling an important gap in medical knowledge.
This study has both strengths and limitations. Strengths include careful matching of control children and measurement of multiple bone markers. Limitations include the small sample size (31 patients), the snapshot nature of the study (which can’t prove cause-and-effect), and lack of long-term follow-up data. The findings are preliminary and should be confirmed in larger studies before changing clinical practice.
What the Results Show
The most striking finding was that healthy children showed lower sclerostin levels during puberty (as expected), but children with CAH did not show this normal decrease. This is important because sclerostin blocks bone formation, so the failure to decrease sclerostin during the critical bone-building years of puberty could harm long-term bone strength.
Children with CAH also had significantly higher osteoprotegerin levels compared to healthy children (p < 0.001, meaning this difference was very unlikely to be due to chance). Osteoprotegerin is a protective protein, but abnormally high levels may indicate the body is trying to compensate for bone problems.
Interestingly, a hormone called 17-hydroxy progesterone (which is elevated in CAH) appeared to influence these bone proteins. Higher 17-hydroxy progesterone was associated with lower osteoprotegerin and higher sclerostin levels. This suggests the disease itself, not just the steroid treatment, may be affecting bone metabolism.
The study found that cumulative steroid dose, vitamin D levels, pubertal status, and sex did not significantly affect sclerostin or osteoprotegerin levels in the CAH patients. This was somewhat surprising and suggests that the disease process itself may be more important than steroid exposure in driving these bone protein changes. Bone mineral density was low (below -1 Z-score) in 80% of both patient and control groups, indicating this may be a broader issue in this population.
This is the first study to examine sclerostin in CAH patients, so direct comparisons are limited. However, previous research has shown that glucocorticoid steroids can weaken bones in other conditions. This study suggests that in CAH, the disease itself (through elevated 17-hydroxy progesterone) may play an equal or greater role than steroid exposure in affecting bone health. The findings align with clinical observations that some CAH patients have bone problems despite careful steroid management.
The study has several important limitations. First, it’s a snapshot study (cross-sectional), so researchers can’t prove that the protein changes actually cause weak bones—only that they’re associated. Second, the sample size is small (31 patients), which limits how much the findings can be generalized. Third, the study didn’t follow children over time, so we don’t know if these protein changes predict future bone problems. Fourth, the study couldn’t separate the effects of the disease from the effects of steroid treatment. Finally, the study measured bone density but didn’t assess actual fracture risk or long-term bone health outcomes.
The Bottom Line
Based on this research, children with CAH should have regular bone health monitoring, especially during puberty when bone mass is being built. Doctors should consider screening for vitamin D deficiency and ensuring adequate calcium intake. Some patients may benefit from vitamin D supplementation. However, these are preliminary findings, and treatment decisions should be made with your child’s endocrinologist. More research is needed before major changes to CAH treatment protocols.
This research is most relevant to children with CAH and their families, pediatric endocrinologists who treat CAH, and researchers studying bone health in chronic disease. Parents of children with CAH should discuss bone health with their doctor. Healthy children and adults without CAH don’t need to change anything based on this study.
Bone health changes develop gradually over years. If your child has CAH, bone monitoring should be ongoing throughout childhood and adolescence. Benefits from vitamin D supplementation or dietary changes typically take several months to show up in bone density measurements. Peak bone mass is built during the teenage years, making this a critical window for intervention.
Frequently Asked Questions
Do children with CAH have weaker bones than other kids?
Children with CAH show abnormal bone-regulating proteins that may affect bone strength. A 2026 study found 80% had low bone density, but more research is needed to determine if this causes actual fractures or long-term problems.
Can steroid medications for CAH damage my child’s bones?
Steroids can affect bone health, but this study suggests the CAH disease itself may be equally important. Cumulative steroid dose didn’t significantly affect bone proteins in this research, indicating disease control matters too.
What can I do to help my child with CAH build strong bones?
Ensure adequate calcium (1,000-1,300 mg daily) and vitamin D intake, encourage weight-bearing exercise, and have regular bone health screening with your endocrinologist. Discuss vitamin D supplementation if your child is deficient.
Is puberty a critical time for bone health in CAH patients?
Yes. This study found CAH patients don’t show the normal sclerostin decrease during puberty that healthy kids do, potentially harming bone mass development during this critical growth window.
Should my child with CAH get bone density testing?
Yes. Talk to your child’s endocrinologist about DEXA scan screening, especially during puberty. Regular monitoring helps detect bone problems early and guide treatment decisions.
Want to Apply This Research?
- Track vitamin D and calcium intake daily, along with any bone health screening results (DEXA scan Z-scores) every 1-2 years. Note any falls or injuries to monitor fracture risk.
- Ensure your child gets adequate calcium (1,000-1,300 mg daily depending on age) and vitamin D (600-1,000 IU daily), and encourage weight-bearing exercise like walking, running, or sports for 30+ minutes most days. Log these activities in the app.
- Create a long-term bone health profile tracking: (1) annual calcium and vitamin D intake, (2) exercise frequency and type, (3) steroid medication doses, (4) DEXA scan results when performed, and (5) any bone-related symptoms or injuries. Share this data with your endocrinologist at each visit.
This article summarizes research findings and is not medical advice. Children with congenital adrenal hyperplasia should have their bone health managed by a qualified pediatric endocrinologist. Do not change medications or treatment without consulting your child’s doctor. This study is preliminary and findings may change as more research is conducted. Always discuss bone health screening and supplementation with your healthcare provider before starting any new regimen.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.